We were asked to share our insights on cell and gene therapy deals and financing in the renowned scientific publication Biopharma Dealmakers by Nature. The take-away: these companies continued to attract large deals in 2022 despite the financing landscape looking gloomier than ever.
The CGT space keeps breaking ground and continues to hold promise for treatment paradigm shifts.
Read the full article titled ‘Industry shows trust in cell and gene therapy platform technologies’ via Nature’s website. Our cell and gene therapy expert Stephanie Mattsson, management consultant, and deal expert Johan Olsson, senior management consultant, at MSC authored the article.
Access article >
Cover photo by Siarhei Yurchanka / Alamy Stock Photo.
